antibodies produced in a primary infection target a lot more than spike protein, in some pre-prints. It's all preliminary data. However, the sinopharm vaccine,

antibodies produced in a primary infection target a lot more than spike protein, in some pre-prints. It's all preliminary data. However, the sinopharm vaccine, which is the whole virus, not just spike protein, seems to lose effectiveness after several months as well.